A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma
Phase of Trial: Phase III
Latest Information Update: 21 Dec 2017
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms HIMALAYA
- Sponsors AstraZeneca
- 14 Nov 2017 Planned primary completion date changed from 27 Feb 2020 to 27 Mar 2020.
- 14 Nov 2017 Status changed from not yet recruiting to recruiting.
- 05 Oct 2017 New trial record